retatrutide patches ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial retatrutide dosing for weight loss

#peptide #investigation | CBS News

So we are going to talk about your heart and your brain and where GLP ones fit into this

Although BED and BN are disabling conditions, the limited treatment options highlight the need for identifying new pharmacological approaches such as glucagon-like peptide-1 receptor agonists (GLP-1RAs)

Ozempic Face or Ozempic Butt: These terms refer to changes in facial and body appearance due to significant weight loss, often leading to sagging skin or a deflated look

See TABLES 2 and 3 for additional counseling points for patients prescribed GLP-1 therapy

3.9 Central nervous system (CNS) Headache is reported in GLP-1 receptor agonist trials ( Table 8 , in the Appendix)